Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CD24 exosomes - OBCTCD24

Next Previous
X
Search
Drug Profile

CD24 exosomes - OBCTCD24

Alternative Names: Coven D24; EXO-CD24

Latest Information Update: 25 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OBCTCD24
  • Developer Nano24; OBCTCD24
  • Class Anti-inflammatories; Biological proteins; Exosome therapies
  • Mechanism of Action Immunosuppressants; Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adult respiratory distress syndrome; COVID 2019 infections
  • Preclinical Autoimmune disorders; Respiratory tract infections

Most Recent Events

  • 04 Jul 2023 Phase-II clinical trials in Adult respiratory distress syndrome in Israel (Inhalation) (NCT05947747)
  • 19 Oct 2022 Efficacy and adverse events data from a phase II trial in COVID-2019 infections presented at the ID Week (IDW-2022)
  • 02 Mar 2022 OBCT CD24 initiates a phase IIb trial for COVID-19 infections (In the adults, In the elderly) in Greece (Inhalation) in March 2022 (EudraCT2021-004259-17)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top